Clinical Scorecard: Differentiation of Pancreatic Ductal Adenocarcinoma from Chronic Pancreatitis Using Macrophage Inhibitory Cytokine 1, Syncollin, and Thrombospondin-2

At a Glance

Key Highlights

• GDF15 and SYCN levels are significantly elevated in PDAC compared to chronic pancreatitis and healthy controls.
• GDF15 shows the strongest discrimination for PDAC vs healthy controls (AUC = 0.86).
• The combined GDF15 + SYCN panel improves diagnostic performance (AUC = 0.89).
• Incorporating age and bilirubin enhances discrimination between PDAC and chronic pancreatitis (AUC = 0.88).
• TSP-2 shows limited diagnostic utility in differentiating PDAC.

Guideline-Based Recommendations

Diagnosis

• Utilize serum GDF15 and SYCN as potential biomarkers for differentiating PDAC from chronic pancreatitis.

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients with suspected pancreatic ductal adenocarcinoma and chronic pancreatitis.

GDF15 and SYCN may serve as adjunctive diagnostic tools in clinical practice.

Clinical Best Practices

• Incorporate multi-marker panels including GDF15 and SYCN for improved diagnostic accuracy.
• Consider patient age and bilirubin levels when evaluating for PDAC.

Related Resources & Content